Recent Advances in Solid Retroperitoneal Tumors
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 3567
Special Issue Editor
Special Issue Information
Dear Colleagues,
Retroperitoneal tumors are a common pathology and relatively frequent reason for surgery in high-volume, specialized centers. At present there are widely accepted diagnostic algorithms and therapeutic guidelines according to the type of neoplasm. Due to the specificity of the retroperitoneal region it can often be quite difficult to perform radical removal. In malignant tumors compartment resection is often necessary. This is the task for a specialized experienced team that can deal even with large vascular resection. Adjuvant oncological therapy is often mandatory; recently there has been a growing conversation surrounding targeted therapy. In this modality, reading the tumor genome is crucial. Great progress has been made over the last 20 years in this field. Thanks to next-generation sequencing we are able to focus on specific gene therapy. In this Special Issue we would like to present a multidisciplinary approach to this heterogenous group of patients, from diagnostic issues to specific immune therapy. There is no doubt that following the guidelines and using all new techniques is beneficial for the patient. This Special Issue is intended not only for surgeons, but also for radiologists, pathologists, gene specialist, oncologists, and for all who come into contact with patients who have been diagnosed with retroperitoneal mass.
Prof. Dr. Jiří Moláček
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retroperitoneal tumor
- surgical therapy
- next-generation sequencing
- targeted therapy
- diagnostic and therapeutic algorithm
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
